STOCK TITAN

Viatris Inc - VTRS STOCK NEWS

Welcome to our dedicated news page for Viatris (Ticker: VTRS), a resource for investors and traders seeking the latest updates and insights on Viatris.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Viatris's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Viatris's position in the market.

Rhea-AI Summary
Viatris Inc. (VTRS) is enhancing its R&D strategy to build a more durable, higher-margin portfolio of patented innovation. The company is collaborating with Idorsia on Phase 3 assets selatogrel and cenerimod, with a focus on pipeline development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.98%
Tags
clinical trial
-
Rhea-AI Summary
Viatris Inc. (VTRS) meets 2023 guidance for total revenues, adjusted EBITDA, and free cash flow. The company reports 2023 total revenues of $15.4 billion, U.S. GAAP net earnings of $54.7 million, adjusted EBITDA of $5.1 billion, and free cash flow of $2.4 billion. Viatris adds two Phase 3 assets with blockbuster revenue potential through a collaboration with Idorsia and completes $250 million in share repurchases in 2024. The Board of Directors increases the share repurchase authorization by an additional $1 billion, maintaining the dividend policy for 2024 at $0.48 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.11%
Tags
earnings
-
Rhea-AI Summary
Viatris expands its portfolio by adding two Phase 3 assets, Selatogrel and Cenerimod, through a collaboration with Idorsia. The deal includes potential for future innovative assets. Selatogrel targets acute myocardial infarction patients, while Cenerimod focuses on systemic lupus erythematosus. The collaboration strengthens Viatris' cardiovascular and immunology offerings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.11%
Tags
none
Rhea-AI Summary
Viatris Inc. (VTRS) is set to reveal its Q4 and full-year 2023 financial results on Feb. 28, 2024, before the opening of the US financial markets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.28%
Tags
earnings
-
Rhea-AI Summary
Viatris Inc. (NASDAQ: VTRS) to Participate in 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
Viatris Inc. (NASDAQ: VTRS) appoints Doretta Mistras as the new CFO, thanking Sanjeev Narula for his role in executing Phase 1 strategy. Mistras brings extensive healthcare financial expertise and experience from top investment banks, with a track record of guiding corporations on strategic decisions totaling over $240 billion in value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management clinical trial
Rhea-AI Summary
Viatris Inc. (NASDAQ: VTRS) announced the re-election of all nominated Directors and the approval of all voting matters at its 2023 Annual Meeting of Shareholders. The Board of Directors has elected Melina Higgins as the new Chair, succeeding Robert J. Coury.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Viatris (VTRS) partners with Comfort Cases to pack 1,000 backpacks for children in foster care as part of its Impact Week Anniversary Celebration. This is the second consecutive year of the partnership, with the company expanding its efforts by also packing backpacks at its offices in Washington, D.C. and New York City. Viatris' mission of empowering people worldwide to live healthier at every stage of life extends beyond medicines to making the world a better place by building healthier communities. Comfort Cases founder, Rob Scheer, personally connected to the cause, expressed gratitude for Viatris' support in ensuring foster children have the support and resources they need to thrive.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.11%
Tags
partnership
-
Rhea-AI Summary
Viatris Inc. (NASDAQ: VTRS) to Participate in Jefferies London Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.02%
Tags
conferences
Rhea-AI Summary
Viatris Inc. (NASDAQ: VTRS) and Theravance Biopharma, Inc. (NASDAQ: TBPH) announce positive Phase III results for YUPELRI in China, demonstrating efficacy and safety for COPD patients. The study shows a statistically significant increase in trough FEV1 compared to placebo, supporting a regulatory filing in China in mid-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
clinical trial
Viatris Inc

Nasdaq:VTRS

VTRS Rankings

VTRS Stock Data

14.18B
1.18B
0.35%
83.41%
3.24%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Canonsburg

About VTRS

mylan is a global pharmaceutical company committed to setting new standards in healthcare. working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. we offer a growing portfolio of around 1,400 generic pharmaceuticals and several brand medications. in addition, we offer a wide range of antiretroviral therapies, upon which nearly 50% of hiv/aids patients in developing countries depend. we also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in about 145 countries and territories. our workforce of approximately 30,000 people is dedicated to creating better health for a better world, one person at a time. learn more at mylan.com.